Retatrutide

What it is

The most potent metabolic peptide in the literature today. It acts on three switches at once for appetite and energy expenditure, instead of on just one like earlier-generation compounds.

Your body has several hormones that tell the brain “that's enough, stop eating.” Retatrutide mimics three of them simultaneously. The first two reduce hunger; the third also makes the body burn more. That is why the published figures are higher than those of any other compound in its family.

What it is used for

• • Research on body weight and appetite control
• • Body recomposition studies: how much fat is lost and how much muscle is preserved
• • Energy expenditure: the branch that sets it apart from the rest
• • Fatty liver and blood sugar control

How it is used

Lyophilized powder. It is reconstituted with bacteriostatic water, swirled without shaking until dissolved, and stored between 2 and 8 °C. In the literature it is administered once a week, always with gradual dose escalation: increasing slowly is what reduces digestive discomfort ^[1].

What has been observed

Results described in the published scientific literature. They are not directions for use or health recommendations.

• • In the phase 2 trial (338 adults, 48 weeks), the 12 mg dose produced a mean body weight reduction of 24.2%, versus 2.1% with placebo ^[1]
• • At 8 mg, 100% of participants lost at least 5% of their weight, 91% at least 10%, and 75% at least 15% ^[1]
• • A phase 2a trial in metabolic fatty liver disease described significant reductions in liver fat content ^[2]
• • Digestive effects were the most frequent: they were dose-dependent, mostly mild or moderate, and were attenuated by starting with a lower initial dose ^[1]
• • A dose-dependent increase in heart rate was observed, peaking at 24 weeks and declining thereafter ^[1]

How it works

GIP / GLP-1 / glucagon triple agonism

Retatrutide (LY-3437943) acts as an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors ^[1]. The first two branches reduce intake centrally and slow gastric emptying.

The glucagon branch

This is what sets it apart from dual agonists. Signaling through the glucagon receptor is associated with increased energy expenditure and mobilization of liver fat, so energy balance is addressed from both sides: less in and more out ^[2][4].

Clinical development

It has completed phase 2 in obesity and in metabolic dysfunction-associated steatotic liver disease, and is in registrational phase 3 in obesity, sleep apnea and knee osteoarthritis, as well as type 2 diabetes ^[2][3].

State of the evidence

Clinical and top-tier. The data come from randomized, placebo-controlled clinical trials published in The New England Journal of Medicine, Nature Medicine and The Lancet ^[1][2][3]. One distinction is worth keeping in mind: those clinical trials were conducted with a pharmaceutical product in patients and under medical supervision. What we offer here is reference material for research, not an approved medicine.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med, 2023. PubMed 37366315
2. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med, 2024. PubMed 38858523
3. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial. Lancet, 2026. PubMed 42250575
4. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. PubMed 40563436